Search - tctmd.com

Displaying 201 - 220 of 419

Sort: Relevancy | Date

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

November 15, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

May 15, 2020

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Better Adherence to Guideline Advice Pays Off After Acute MI

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

Ultra LOW LDL is the target for high risk patients

Presentation JIM 2020

Ultra LOW LDL is the target for high risk patients

Presenter: Francesco Prati

February 13, 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presentation JIM 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presenter: Ferdinando Varbella

February 13, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

January 31, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.